Aula sobre Trasplantes de Órganos Sólidos - Roche Trasplantes

More documents

Recommendations

Info

Clínica y Diagnóstico - Ponencias7. Tullius SG, Hancock W, Heemann U, Azuma H, Tilney N. Reversibilityof chronic renal allograft rejection. Transplantation1994; 58: 93-99.8. González Molina M, Serón D, García del Moral R, et al. forthe Spanish Mycophenolate Mofetil and Chronic Graft NephropathyStudy Group. Treatment of chronic allograft nephropathywith mycophenolate mofetil after kidney transplantation.A Spanish multicenter study. Transplant Proc (in press).9. Isoniemi HM, Krogerus L, Von Willebrand E, et al. Histopathologicalfindings in well functioning long term renal allografts.Kidney Int 1992; 41:155-160.10. Dimény E, Wahlberg J, Larsson E, Fellström B. Can histopathologicalfindings in early renal allograft biopsies identifypatients at risk for chronic vascular rejection? Clin Transplant1995; 9: 79-84.11. Serón D, Moreso F, Bover J, et al. Early protocol renal allograftbiopsies and graft outcome. Kidney Int 1997; 51: 310-317.12. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2year protocol biopsies from a U.S. multicenter kidney transplanttrial comparing tacrolimus versus Cyclosporine. Transplantation1998; 66: 1736-1740.13. Rush ND, Jeffery JR, Gough J. Sequential protocol biopsies inrenal transplant patients. Transplantation 1995; 50: 511-514.14. Legendre C, Thervet E, Skhiri H, et al. Histologic features ofchronic allograft nephropathy revealed by protocol biopsiesin kidney transplant recipients. Transplantation 1998; 65:1506-1509.15. Serón D, Moreso F, Ramón JM, et al. Protocol renal allograftbiopsies and the design of clinical trials aimed to prevent ortreat chronic allograft nephropathy. Transplantation 2000;69:1849-1855.16. Uretsky BF, Murali S, Reddy PS, et al. Development of coronaryartery disease in cardiac transplant patients receivingimmunopsuppressive therapy cyclosporine and prednisone.Circulation 1987; 76: 827-834.17. Kobashigawa JA, Katznelson S, Laks H, M et al. Effect ofpravastatin on outcomes after cardiac transplantation. N EnglJ Med 1995; 333: 621-627.18. Wang H, Kjellstrand CM, Cockfield SM. Solez K. On the influenceof sample size on the prognostic accuracy and reproducibilityof renal transplant biopsy. Nephrol Dial Transplant1998;13: 165-172.19. Bosmans JL, Woestenburg A, Ysebaert DK, Chapelle T, HelbertMJ, Corthouts R et al. Fibrous intimal thickening at implantationas a risk factor for outcome of cadaveric renal allografts.Transplantation 2000; 69: 2388-2394.20. Marcussen M, Olsen TS, Benediktsson H, Racusen L, SolezK. Reproducibility of the Banff classification of renal allograftpathology. Transplantation 1995; 60: 1083-1089.21. Furness PN, Kirkpatrick U, Taub N, Davies DR, Solez K. AUK-wide trial of the Banff classification of renal transplantpathology in routine diagnostic practice. Nephrol Dial Transplant1997; 12: 995-1000.22. Furness PN, Taub N, Assmann K, et al. International variationin the interpretation of renal transplant biopsies. KidneyInt (in press)23. Moreso F, Lopez M, Vallejos A, et al. Serial protocol biopsiesto quantify the progression of chronic transplant nephropathyin stable renal allografts. Am J Transplantation 2001; 1: 82-88.24. Nicholson ML, McCulloch TA, Harper SJ, et al. Early measurementof interstitial fibrosis predicts long term renal functionand graft survival in renal transplantation. British J Surg1996; 83: 1082-1085.25. Nicholson ML, Bailey E, Williams S, Harris PG, FurnessPN. Computarized histomorphometric assessmentof protocol renal transplant biopsy specimens for surrogatemarkers of chronic rejection. Transplantation1999; 68: 236-241.26. Faye Sweat HT, Holde Puchtler MD, Sanford IR, Augusta GA:Sirius Red F3BA as a stain for connective tissue. Archives Pathol1981; 78: 69-72.27. Moreso F, Serón D, Vitrià J, et al. Quantification of interstitialchronic renal damage by means of texture analysis. KidneyInt 1994; 46: 1721-1727.28. Masseroli M, O’Valle F, Andújar M, et al. Design and validationof a new image analysis method for authomatic quantificationof interstitial fibrosis and glomerular morphometry.Lab Invest 1998; 78: 511-522.29. Nickerson P, Jeffry J, Cough J, et al. Identification of clinicaland histological risk factors for diminished renal function 2years posttransplant. J Am Soc Nephrol 1998; 9: 482-487.30. Hunsicker LG, Bennet LE. Design of trials of methods to reducelate renal allograft loss: the price of success. Kidney Int1995; 48 (Suppl 52) : 120-123.123
Clínica y Diagnóstico - PresentaciónPresentaciónDaniel SerónDiapositiva 1 Diapositiva 2Diapositiva 3 Diapositiva 4125
Page 1 and 2:
Aula sobreTrasplantesde ÓrganosSó
Page 3 and 4:
DRUGEdificio Vértice Antonio Lópe
Page 5 and 6:
Índice de AutoresCoordinadoresV. C
Page 8 and 9:
CONCEPTOy EPIDEMIOLOGÍA
Page 10 and 11:
jerto es muy alta en los tres tipos
Page 12 and 13:
Además, se consideró la presencia
Page 14 and 15:
pretrasplante de cardiopatía isqu
Page 16 and 17:
15- Miller L, Kobashigawa J, Valant
Page 18 and 19:
Diapositiva 5 Diapositiva 6Diaposit
Page 20 and 21:
Diapositiva 17 Diapositiva 18Diapos
Page 22 and 23:
Además, cada vez estos trasplantad
Page 24 and 25:
de lo mismo, la necrosis más recha
Page 26 and 27:
Concepto y epidemiología - Present
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Concepto y epidemiología - Ponenci
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 43 and 44:
Patogenia y Factores de Riesgo - In
Page 45 and 46:
Patogenia y Factores de Riesgo - Po
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Diapositiva 17 Diapositiva 18Diapos
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64: Patogenia y Factores de Riesgo - Po
Page 67 and 68: Diapositiva 5 Diapositiva 6Diaposit
Page 73 and 74: Patogenia y Factores de Riesgo - Pr
Page 79: CLÍNICAy DIAGNÓSTICO
Page 82 and 83: En el trasplante hepático el diagn
Page 84 and 85: anormal. A pesar de las limitacione
Page 86 and 87: en ella-, en la actualidad existe y
Page 88 and 89: dio basal para, posteriormente, pod
Page 90 and 91: arteriopatía del injerto en alguno
Page 92 and 93: Clínica y Diagnóstico - Presentac
Page 100 and 101: marcador de función de las célula
Page 102 and 103: son las de grande y mediano calibre
Page 104 and 105: Clinica y Diagnostico - Presentaci
Page 106 and 107: Clinica y Diagnostico - Presentaci
Page 108 and 109: Clínica y Diagnóstico - Ponencias
Page 116 and 117: Diapositiva 5 Diapositiva 6Diaposit
Page 118 and 119: Diapositiva 17 Diapositiva 18Diapos
Page 120: TRATAMIENTOy PREVENCIÓN
Page 123 and 124: Tratamiento y Prevención - Ponenci
Page 133 and 134: Tratamiento y Prevención - Present
Page 139 and 140: vascular del injerto, no hay por el
Page 141 and 142: ación de una importante variedad d
Page 143 and 144: BIBLIOGRAFÍA1. Costanzo MR, Naftel
Page 151 and 152: te debida a la reducción de la inc
Page 153 and 154: tos secundarios adversos a la inmun
Page 155 and 156: elación a la necesidad de retraspl
show all

Aula sobre Trasplantes de Órganos Sólidos - Roche Trasplantes

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?